SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 1998 Commission File Number 0-19041 American Biogenetic Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 11-2655906 (State or other jurisdiction (I.R.S.Employer Identification No.) of incorporation or organization) 1375 Akron Street 516-789-2600 Copiague, New York 11726 (Telephone number) (Address of principal executive offices) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES X NO Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. Class Outstanding at August 7, 1998 Class A Common Stock, par value $.001 20,649,945 Class B Common Stock, par value $.001 1,775,500 Page 1 AMERICAN BIOGENETIC SCIENCES, INC. AND SUBSIDIARY (a development stage company) Form 10-Q for the Quarter Ended June 30, 1998 INDEX Part I - FINANCIAL INFORMATION Item 1: Financial Statements: Page No. Consolidated Balance Sheets - June 30, 1998 and December 31, 1997 3 Consolidated Statements of Operations - Three and Six Months Ended June 30, 1998 and June 30, 1997 and For the Period from Inception (September 1, 1983) Through June 30, 1998 4 Consolidated Statements of Cash Flows - Six Months Ended June 30, 1998 and June 30, 1997 and For the Period from Inception (September 1, 1983) Through June 30, 1998 5 Consolidated Statements of Stockholders' Equity - For the Period from Inception (September 1, 1983) Through June 30, 1998 6 - 8 Notes to Consolidated Financial Statements 9 - 14 Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations 14 - 19 Part II - OTHER INFORMATION Item 2: Changes in Securities 19 - 20 Item 4: Submission of Matters to a Vote of Security Holders 20 - 21 Item 5: Other Events 21 - 22 Item 6: Exhibits and Reports on Form 8-K 22 Signature 22 Page 2 AMERICAN BIOGENETIC SCIENCES, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED BALANCE SHEETS June 30, December 31, Assets 1998 1997 ------------ ------------ (Unaudited) Current Assets: Cash and cash equivalents $7,661,000 $7,121,000 Accounts receivable 306,000 - Inventory 445,000 296,000 Other current assets 23,000 41,000 ------------ ------------ Total current assets 8,435,000 7,458,000 ------------ ------------ Fixed assets, at cost, net of accumulated depreciation and amortization of $1,628,000 and $1,481,000, respectively 697,000 511,000 Patent costs, net of accumulated amortization of $340,000 and $292,000, respectively 1,385,000 1,337,000 Debt issuance costs, net of accumulated amortization of $564,000 and $520,000, respectively 516,000 59,000 Intangible assets 594,000 - Other assets 22,000 23,000 ------------ ------------ $11,649,000 $9,388,000 ============ ============ Liabilities and Stockholders' Equity Current Liabilities: Accounts payable and accrued expenses $1,210,000 $494,000 Current portion of capital lease obligation 3,000 3,000 ------------ ------------ Total current liabilities 1,213,000 497,000 ------------ ------------ Long Term Liabilities: Notes Payable 159,000 - 5% convertible debentures, net of unamortized debt discount of $698,000 and $0, respectively 3,302,000 - 7% convertible debentures - 1,350,000 8% convertible debentures 500,000 850,000 Long-term portion of capital lease obligation 7,000 8,000 ------------ ------------ Total liabilities 5,181,000 2,705,000 ------------ ------------ Stockholders' Equity: Class A common stock, par value $.001 per share; 50,000,000 shares authorized; 20,649,945 and 19,341,617 shares issued and outstanding, respectively 21,000 19,000 Class B common stock, par value $.001 per share; 3,000,000 shares authorized; 1,775,500 and 1,725,500 shares issued and outstanding, respectively 2,000 2,000 Additional paid-in capital 58,773,000 56,077,000 Deficit accumulated during the development stage (52,328,000) (49,415,000) ------------ ------------ Total stockholders' equity 6,468,000 6,683,000 ------------ ------------ $11,649,000 $9,388,000 ============ ============ See notes to unaudited consolidated financial statements Page 3 AMERICAN BIOGENETIC SCIENCES, INC. AND SUBSIDIARY (a development stage company) CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the Period From Inception Three Months Ended Six Months Ended (September 1, -------------------------- ------------------------------ 1983) Through June 30, June 30, June 30, June 30, June 30, 1998 1997 1998 1997 1998 ------------ ------------ -------------- -------------- -------------- Revenues: Sales $327,000 $ - $441,000 $ - $591,000 Royalties / license fees - - - - 1,000,000 Collaborative agreements - - - 9,000 302,000 ------------ ------------ -------------- -------------- -------------- 327,000 - 441,000 9,000 1,893,000 Expenses: Cost of sales 106,000 - 142,000 - 174,000 Research and development 580,000 914,000 1,076,000 1,972,000 27,721,000 Selling, general and administrative 1,095,000 891,000 2,131,000 1,977,000 26,792,000 ------------ ------------ -------------- -------------- -------------- Loss from operations (1,454,000) (1,805,000) (2,908,000) (3,940,000) (52,794,000) ------------ ------------ -------------- -------------- -------------- Other Income (Expense): Interest expense (127,000) (126,000) (176,000) (813,000) (3,918,000) Net gain on sale of fixed assets - - - - 7,000 Net investment income 85,000 151,000 171,000 326,000 4,377,000 ------------ ------------ -------------- -------------- -------------- Net loss ($1,496,000) ($1,780,000) ($2,913,000) ($4,427,000) ($52,328,000) ============ ============ ============== ============== ============== Per Share Information (Note 3): Net loss per common share: Basic ($0.07) ($0.09) ($0.14) ($0.23) ============ ============ ============== ============== Diluted ($0.07) ($0.09) ($0.14) ($0.23) ============ ============ ============== ============== Common shares used in computing per share amounts: Basic 21,726,000 20,024,000 21,505,000 19,306,000 ============ ============ ============== ============== Diluted 21,726,000 20,024,000 21,505,000 19,306,000 ============ ============ ============== ============== See notes to unaudited consolidated financial statements Page 4 AMERICAN BIOGENETIC SCIENCES, INC. AND SUBSIDIARY (a development stage company) CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Period From Inception (September 1, Six Months Ended 1983) -------------------------- Through June 30, June 30, June 30, 1998 1997 1998 ------------ ------------ -------------- Cash Flows From Operating Activities: Net loss ($2,913,000) ($4,427,000) ($52,328,000) Adjustments to reconcile net (loss) to net cash provided or (used) in operating activities: Depreciation and amortization 249,000 297,000 2,474,000 Net gain on sale of fixed assets - - (7,000) Net gain on sale of marketable securities - - (217,000) Other non-cash expenses accrued primarily for stocks and warrants 51,000 102,000 1,787,000 Amortization of debt discount included in interest expense 64,000 492,000 1,907,000 Write off of patent costs - - 93,000 (Increase) decrease in accounts receivable (198,000) - (198,000) (Increase) decrease in inventory (9,000) - (305,000) (Increase) decrease in other current assets (18,000) 470,000 (59,000) (Increase) decrease in other assets (5,000) (5,000) 67,000 Increase (decrease) in accounts payable and accrued expenses 736,000 59,000 1,447,000 Increase in interest payable to stockholder - - 112,000 ------------ ------------ -------------- Net cash provided by (used in) operating activities (2,043,000) (3,012,000) (45,227,000) ------------ ------------ -------------- Cash Flows From Investing Activities: Capital expenditures (14,000) (192,000) (2,016,000) Proceeds from sale of fixed assets - - 18,000 Payments for patent costs and other assets (96,000) (219,000) (1,795,000) Business acquisition, net of stock issued and cash acquired (119,000) - (119,000) Proceeds from maturity and sale of marketable securities - 5,817,000 67,549,000 Purchases of marketable securities - (2,796,000) (67,332,000) ------------ ------------ -------------- Net cash provided by (used in) investing activities (229,000) 2,610,000 (3,695,000) ------------ ------------ -------------- Cash Flows From Financing Activities: Payments to debentureholders (1,000,000) (1,122,000) (2,246,000) Proceeds from issuance of common stock, net 98,000 388,000 36,400,000 Proceeds from issuance of 5% convertible debentures, net 3,727,000 - 3,727,000 Proceeds from issuance of 7% convertible debentures, net - - 8,565,000 Proceeds from issuance of 8% convertible debentures, net - - 7,790,000 Principal payments under capital lease obligation and notes payable (13,000) - (22,000) Capital contributions from chairman - - 1,000,000 Increase in loans payable to stockholder / affiliates - - 2,669,000 Repayment of loans payable to stockholder and affiliates (remainder contributed to capital by the stockholder) - - (1,300,000) ------------ ------------ -------------- Net cash provided by (used in) financing activities 2,812,000 (734,000) 56,583,000 ------------ ------------ -------------- Net Increase (Decrease) in Cash and Cash Equivalents 540,000 (1,136,000) 7,661,000 Cash and Cash Equivalents at Beginning of Period 7,121,000 10,760,000 - ------------ ------------ -------------- Cash and Cash Equivalents at End of Period $7,661,000 $9,624,000 $7,661,000 ============ ============ ============== Supplemental Disclosure of Noncash Activities: Capital expenditures made under capital lease obligation - - $20,000 ============ ============ ============== Convertible Debentures converted into 851,618, 2,893,492, and 6,470,583 shares of Common Stock, respectively $1,334,000 $8,104,000 $14,545,000 ============ ============ ============== Warrants issued to debentureholders and placement agent $252,000 - $777,000 ============ ============ ============== See notes to unaudited consolidated financial statements Page 5 AMERICAN BIOGENETIC SCIENCES, INC. AND SUBSIDIARY (a development stage company) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Class A Class B Per Common Stock Common Stock Share --------------------------- ------------------------ Amount Shares Dollars Shares Dollars ------- ------------ ------------- ----------- ----------- BALANCE, AT INCEPTION, (SEPTEMBER 1, 1983) $ - $ - - $ - Sale of common stock to chairman for cash .33 78,000 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1983 78,000 - - - Sale of common stock to chairman for cash .33 193,500 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1984 271,500 - - - Sale of common stock to chairman for cash .33 276,700 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1985 548,200 1,000 - - Sale of common stock to chairman for cash .33 404,820 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1986 953,020 1,000 - - Sale of common stock to chairman for cash .33 48,048 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1987 1,001,068 1,000 - - Exchange of common stock for Class B stock (1,001,068) (1,000) 1,001,068 1,000 Sale of Class B stock to chairman for cash .33 - - 1,998,932 2,000 Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1988 - - 3,000,000 3,000 Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1989 - - 3,000,000 3,000 Conversion of loans payable to stockholder into additional paid-in capital - - - - Sale of 1,150,000 Units to public consisting of 3,450,000 shares of Class A common stock and warrants (net of $1,198,000 underwriting expenses) 2.00 3,450,000 3,000 - - Conversion of Class B stock into Class A stock 668,500 1,000 (668,500) (1,000) Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1990 4,118,500 $4,000 2,331,500 $2,000 ------------ ------------- ----------- ----------- CONTINUED Page 6 BALANCE, DECEMBER 31, 1990 4,118,500 $4,000 2,331,500 $2,000 Exercise of Class A Warrants (net of $203,000 in underwriting expenses) for cash 3.00 3,449,955 3,000 - - Exercise of Class B Warrants for cash 4.50 79,071 - - - Conversion of Class B stock into Class A stock 850,000 1,000 (850,000) (1,000) Exercise of stock options 2.00 417,750 1,000 - - Expense for warrants issued - - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1991 8,915,276 9,000 1,481,500 1,000 Exercise of Class B Warrants (net of $701,000 in underwriting expenses) for cash 4.50 3,370,884 3,000 - - Conversion of Class B stock into Class A stock 106,000 - (106,000) - Exercise of stock options 2.49 348,300 1,000 - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1992 12,740,460 13,000 1,375,500 1,000 Sale of common stock to Medeva PLC. 7.50 200,000 - - - Exercise of stock options 2.00 32,700 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1993 12,973,160 13,000 1,375,500 1,000 Exercise of stock options 2.16 91,250 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1994 13,064,410 13,000 1,375,500 1,000 Conversion of 8% Convertible Debentures into Class A Common Stock 1.85 354,204 - - - Exercise of stock options 1.82 12,750 - - - Expense for warrants/options issued - - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1995 13,431,364 $13,000 1,375,500 $1,000 ------------ ------------- ----------- ----------- CONTINUED Page 7 ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1995 13,431,364 $13,000 1,375,500 $1,000 Conversion of 8% Convertible Debentures into Class A Common Stock 2.74 2,269,755 2,000 - - Exercise of stock options 2.53 569,875 1,000 - - Expense for warrants/options issued - - - - Discount on 7% convertible debentures - - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 30, 1996 16,270,994 16,000 1,375,500 1,000 ------------ ------------- ----------- ----------- Conversion of 7% and 8% Convertible Debentures into Class A Common Stock 2.93 2,995,006 3,000 - - Sale of Class B Common Stock for cash 2.23 - - 350,000 1,000 Exercise of stock options 2.00 27,500 - - - Expense for warrants issued - - - - Class A Common Stock issued 3.12 48,117 - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, DECEMBER 31, 1997 19,341,617 $19,000 1,725,500 $2,000 ============ ============= =========== =========== Conversion of 7% and 8% Convertible Debentures into Class A Common Stock 0.92 851,618 1,000 - - Sale of Class B Common Stock for cash 1.62 - - 50,000 - Exercise of stock options 1.75 4,000 - - - Expense for warrants issued - - - - Class A Common Stock issued 1.57 54,304 - - - Class A Common Stock issued for Stellar 1.76 398,406 1,000 - - Discount on 5% convertible debentures - - - - Net (loss) for the period - - - - ------------ ------------- ----------- ----------- BALANCE, JUNE 30, 1998 20,649,945 $21,000 1,775,500 $2,000 ============ ============= =========== =========== See notes to unaudited consolidated financial statements Page 8 AMERICAN BIOGENETIC SCIENCES, INC. AND SUBSIDIARY (a development stage company) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Deficit Accumulated Additional During the Paid-in Development Capital Stage Total ------------ ------------- ----------- BALANCE, AT INCEPTION, (SEPTEMBER 1, 1983) $ - $ - $ - Sale of common stock to chairman for cash 26,000 - 26,000 Net (loss) for the period - (25,000) (25,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1983 26,000 (25,000) 1,000 Sale of common stock to chairman for cash 65,000 - 65,000 Net (loss) for the period - (242,000) (242,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1984 91,000 (267,000) (176,000) Sale of common stock to chairman for cash 92,000 - 92,000 Net (loss) for the period - (305,000) (305,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1985 183,000 (572,000) (388,000) Sale of common stock to chairman for cash 134,000 - 134,000 Net (loss) for the period - (433,000) (433,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1986 317,000 (1,005,000) (687,000) Sale of common stock to chairman for cash 16,000 - 16,000 Net (loss) for the period - (730,000) (730,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1987 333,000 (1,735,000) (1,401,000) Exchange of common stock for Class B stock - - - Sale of Class B stock to chairman for cash 664,000 - 666,000 Net (loss) for the period - (1,031,000) (1,031,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1988 997,000 (2,766,000) (1,766,000) Net (loss) for the period - (1,522,000) (1,522,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1989 997,000 (4,288,000) (3,288,000) Conversion of loans payable to stockholder into additional paid-in capital 1,481,000 - 1,481,000 Sale of 1,150,000 Units to public consisting of 3,450,000 shares of Class A common stock and warrants (net of $1,198,000 underwriting expenses) 5,699,000 - 5,702,000 Conversion of Class B stock into Class A stock - - - Net (loss) for the period - (2,100,000) (2,100,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1990 $8,177,000 ($6,388,000) $1,795,000 ------------ ------------- ----------- CONTINUED Page 6 (column continuation) BALANCE, DECEMBER 31, 1990 $8,177,000 ($6,388,000) $1,795,000 Exercise of Class A Warrants (net of $203,000 in underwriting expenses) for cash 10,143,000 - 10,146,000 Exercise of Class B Warrants for cash 356,000 - 356,000 Conversion of Class B stock into Class A stock - - - Exercise of stock options 835,000 - 836,000 Expense for warrants issued 900,000 - 900,000 Net (loss) for the period - (4,605,000) (4,605,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1991 20,411,000 (10,993,000) 9,428,000 Exercise of Class B Warrants (net of $701,000 in underwriting expenses) for cash 14,465,000 - 14,468,000 Conversion of Class B stock into Class A stock - - - Exercise of stock options 865,000 - 866,000 Net (loss) for the period - (4,016,000) (4,016,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1992 35,741,000 (15,009,000) 20,746,000 Sale of common stock to Medeva PLC. 1,500,000 - 1,500,000 Exercise of stock options 65,000 - 65,000 Net (loss) for the period - (6,521,000) (6,521,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1993 37,306,000 (21,530,000) 15,790,000 Exercise of stock options 197,000 - 197,000 Net (loss) for the period - (7,431,000) (7,431,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1994 37,503,000 (28,961,000) 8,556,000 Conversion of 8% Convertible Debentures into Class A Common Stock 571,000 - 571,000 Exercise of stock options 23,000 - 23,000 Expense for warrants/options issued 602,000 - 602,000 Net (loss) for the period - (5,607,000) (5,607,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1995 $38,699,000 ($34,568,000) $4,145,000 ------------ ------------- ----------- CONTINUED Page 7 (column continuation) BALANCE, DECEMBER 31, 1995 $38,699,000 ($34,568,000) $4,145,000 Conversion of 8% Convertible Debentures into Class A Common Stock 5,483,000 - 5,485,000 Exercise of stock options 1,438,000 - 1,439,000 Expense for warrants/options issued 330,000 - 330,000 Discount on 7% convertible debentures 1,843,000 - 1,843,000 Net (loss) for the period - (7,700,000) (7,700,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1996 47,793,000 (42,268,000) 5,542,000 ------------ ------------- ----------- Conversion of 7% and 8% Convertible Debentures into Class A Common Stock 7,152,000 - 7,155,000 Sale of Class B Common Stock for cash 778,000 - 779,000 Exercise of stock options 55,000 - 55,000 Expense for warrants issued 149,000 - 149,000 Class A Common Stock issued 150,000 - 150,000 Net (loss) for the period - (7,147,000) (7,147,000) ------------ ------------- ----------- BALANCE, DECEMBER 31, 1997 $56,077,000 ($49,415,000) $6,683,000 ============ ============= =========== Conversion of 7% and 8% Convertible Debentures into Class A Common Stock 759,000 - 760,000 Sale of Class B Common Stock for cash 81,000 - 81,000 Exercise of stock options 7,000 - 7,000 Expense for warrants issued 303,000 - 303,000 Class A Common Stock issued 85,000 - 85,000 Class A Common Stock issued for Stellar 699,000 - 700,000 Discount on 5% convertible debentures 762,000 - 762,000 Net (loss) for the period - (2,913,000) (2,913,000) ------------ ------------- ----------- BALANCE, JUNE 30, 1998 $58,773,000 ($52,328,000) $6,468,000 ============ ============= =========== See notes to unaudited consolidated financial statements CONTINUED Page 8 (column continuation) AMERICAN BIOGENETIC SCIENCES, INC. AND SUBSIDIARY (a development stage company) NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) June 30, 1998 (1) INTERIM FINANCIAL STATEMENTS The interim unaudited consolidated financial statements presented herein have been prepared in accordance with generally accepted accounting principles for interim financial statements and with the instructions to Form 10-Q and Regulation S-X pertaining to interim financial statements. Accordingly, they do not include all information and footnotes required by generally accepted accounting principles for complete financial statements. The interim financial statements presented herein reflect all adjustments (consisting of normal recurring adjustments and accruals) which, in the opinion of management, are necessary for a fair presentation of financial position as of June 30, 1998 and results of operations for the three and six months ended June 30, 1998 and June 30, 1997. The Company's financial statements should be read in conjunction with the summary of significant accounting policies and the notes to consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 1997. The results of operations for interim periods are not necessarily indicative of the results for a full year. (2) RECENTLY ISSUED ACCOUNTING STANDARDS In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No.133, "Accounting for Derivative Instruments and Hedging Activities ". The Statement establishes accounting and reporting standards requiring that every derivative instrument (including certain derivative instruments embedded in other contracts) be recorded in the balance sheet as either an asset or liability measured at its fair value. The Statement requires that Page 9 changes in the derivative's fair value be recognized currently in earnings unless specific hedge accounting criteria are met. Special accounting for qualifying hedges allows a derivative's gains and losses to offset related results on the hedged item in the income statement, and requires that a company must formally document, designate, and assess the effectiveness of transactions that receive hedge accounting. SFAS No.133 is effective for fiscal years beginning after June 15, 1999. A company may also implement the Statement as of the beginning of any fiscal quarter after June 16, 1998. SFAS No.133 cannot be applied retroactively. SFAS No.133 must be applied to (a) derivative instruments and (b) certain derivative instruments embedded in hybrid contracts that were issued, acquired, or substantively modified after December 31, 1997 (and, at the Company's election, before January 1, 1998). While the Company operates in international markets, it does so presently without the use of derivatives hedging instruments, and therefore this new pronouncement is not applicable. (3) NET LOSS PER SHARE Basic net loss per common share ("Basic EPS") is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share ("Diluted EPS") is computed by dividing net loss by the weighted average number of common shares and, if any, potential dilutive common shares. SFAS No. 128 requires the presentation of both Basic EPS and Diluted EPS on the face of the consolidated statements of operations. Diluted EPS for 1997 and 1998 is the same as Basic EPS because the inclusion of stock options and convertible debentures outstanding would be antidilutive. Page 10 (4) STOCKHOLDERS' EQUITY Stock Options - The following summarizes the stock option activity in all stock option plans for the three months ended June 30, 1998. Shares Price Granted 114,000 $1.00 - $1.75 Exercised 4,000 $1.75 Cancelled 89,750 $1.75 - $5.50 Each option entitles the holder to purchase one share of Class A Common Stock of the Company. Other Shares and Warrants - In connection with a lease agreement for certain facilities, the Company may, at its option, pay a portion of the annual lease obligation with Class A Common Stock plus warrants. The number of shares of Common Stock is to be computed using the average market price of the Company's Class A Common Stock during the ten days prior to issuance. The warrants are to be exercisable during a period of four years from the date of issuance at a price equal to the closing price of the underlying Class A Common Stock on the date the warrant is issued. The Company issued 25,528 shares of Class A Common Stock during the quarter ended June 30, 1998, as well as a warrant to purchase 25,528 shares of Class A Common Stock at an exercise price of $1.38 per share. The Company has recorded a noncash charge of $23,000 which represents the fair value of the warrant. (5) LONG TERM LIABILITIES On May 20, 1998, the Company completed a private placement to three accredited investors (the "Investors") of an aggregate of $4,000,000 of 5% Convertible Debentures due May 20, 2001 (the "Debentures"), and three series of Warrants to purchase up to an aggregate of 261,288 shares of the Company's Class A Common Stock (the "Warrants"). The Debentures will become convertible to the extent of 25% of the principal amount thereof commencing on September 17, 1998, with an additional 25% of the principal amount of the Debentures becoming first convertible on each of Page 11 October 17, 1998, November 16, 1998 and December 16, 1998 (subject to potential acceleration in certain instances) at a conversion price equal to 87% (if converted before November 17, 1998), 86% (if converted between November 17, 1998 and February 14, 1999), 85% (if converted between February 15, 1999 and May 20, 1999) or 84% (if converted after May 20, 1999), respectively, of the average of the closing bid prices of the Company's Class A Common Stock for the five consecutive trading days immediately preceding the date of conversion of the Debentures (the "Variable Conversion Price"); provided, however, that in no event may the conversion price be greater than $1.9375 per share, which was 125% of such average price over the five consecutive trading days prior to the consummation of the transaction (the "Fixed Conversion Price"). Interest on the Debentures is payable only on maturity, conversion, redemption or when other payment is made on the Debentures in cash or, if registered for resale under the Securities Act of 1933, as amended (the "Securities Act"), in shares of the Company's Class A Common Stock valued at the applicable Debenture conversion price. Any Debentures outstanding on May 20, 2001 will be automatically converted into Class A Common Stock of the Company as of that date. In addition, the Company may require conversion of outstanding Debentures after May 20, 2000 if the closing bid price of its Class A Common Stock on the trading day immediately preceding its giving of notice of conversion to Debenture holders is at least $3.0625. In the event the Company would be required to issue more than 4,000,000 shares of its Class A Common Stock upon conversion of all of the Debentures (the "Conversion Limit"), the Company will have the option of: (i) issuing additional shares of Common Stock if stockholder approval has been obtained or if stockholder approval is not required in order to comply with applicable rules of the market upon which its Class A Common Stock is traded or (ii) paying cash to the holder in an amount equal to the principal amount of Debentures being converted plus an amount equal to the number of shares of Class A Common Stock that would be otherwise issuable upon conversion of the Debentures multiplied by the difference between the highest sales price of the Company's Common Stock on the date of conversion and the applicable Debenture conversion price. In the event of a merger or other business combination or corporate reorganization, as a result of which the stockholders of the Company immediately prior thereto own in the aggregate less than 50% of the voting power of the ultimate parent resulting from such transaction, or the Company transfers all or Page 12 substantially all of its assets to another person, then the Debenture holders may participate in such transaction as a class on the same basis as if the Debentures had been converted. In the event a purchase, tender or exchange offer is made and accepted by the holders of more than 50% of the voting power of all outstanding shares of Common Stock immediately prior thereto, the holders of the Debentures are entitled to redeem any outstanding Debentures at a redemption price equal to 115% of the then outstanding principal amount of the Debentures plus accrued interest on the Debentures. The Company also issued to the Investors the Warrants in series entitling the Investors to purchase, at an exercise price of $1.9141 per share, an aggregate of 65,307 shares of the Company's Class A Common Stock at any time to and including May 19, 2002, 65,307 shares of the Company's Common Stock (subject to pro rata reduction to the extent the original principal amount of the Debentures issued to the Investors is not outstanding on the day such Warrant is first exercised) at any time between November 20, 1998 and November 19, 2002, and 130,614 shares of the Company's Class A Common Stock (subject to pro rata reduction to the extent the original principal amount of the Debentures issued to the Investors is not outstanding on the day such Warrant is first exercised) at any time between May 20, 1999 and May 19, 2003. In conjunction with this offering, the Company incurred both cash and noncash issuance costs totaling $525,000. These issuance costs are being amortized as a component of interest expense over the term of the Debentures. Upon conversion of the Debentures, the related unamortized deferred financing costs are charged to paid-in capital. The estimated noncash value of the Warrants; $252,000, has been recorded as additional paid-in capital, while their cost is included in the $525,000 total issuance costs related to these Debentures. In addition, the Company recorded additional paid-in capital and debt discount of $762,000 to reflect the dollar value of the maximum market price conversion discount (16%) related to these Debentures. The debt discount is being amortized and charged to interest expense from May 20, 1998 through May 20, 1999, the period during which the Debentures become 100% convertible and the maximum discount rate becomes applicable. Page 13 (6) ACQUISITION On April 23, 1998, the Company acquired all of the capital stock of Stellar Bio Systems, Inc., ("Stellar"), a manufacturer of immunodiagnostic kits and reagents. The purchase price was $120,000 in cash and $700,000 in Class A Common Stock (398,406 shares were issued) plus future contingent payments of $650,000 in Class A Common Stock to be paid over three years based upon future sales levels of Stellar. The acquisition was accounted for by the purchase method. Stellar is not considered a significant subsidiary under the Securities and Exchange Commission Regulations S-X. Results of operations have been included in the Company's consolidated financial statements since the date of acquisition. The excess of the aggregate purchase price over the fair market value of net assets acquired of $604,000 has been allocated to intangible assets and goodwill, and will be amortized over a 10 year period. Any additional payments made when the contingency is resolved will be accounted for as additional goodwill and will be amortized over the remaining life of the goodwill. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The Company's results of operations include the results of operations of Stellar Bio Systems, Inc. ("Stellar") from April 23, 1998, the date of its acquisition by the Company. Results of Operations Three Months ended June 30, 1998 The Company's net loss decreased by $284,000 (16%) during the three months ended June 30, 1998 from $1,780,000 in the 1997 period to $1,496,000 in the 1998 period. The decrease is attributable to profit contributions by Stellar Bio Systems and sales of TpP , the Company's Page 14 Thrombus Precursor Protein diagnostic test, a decrease in R&D expenses ($334,000), offset by an increase in SG&A ($204,000) and a reduction in investment income ($66,000). Sales during the three months ended June 30, 1998 were $327,000, consisting of sales of Stellar products since the date of acquisition of Stellar in late April 1998 and sales of TpP by the Company, sales of which products commenced in the fourth quarter of 1997. Accordingly, there were no sales by the Company in the comparable 1997 period. Cost of sales for the three months ended June 30, 1998 was $106,000 or 32% of sales. Research and development expenses decreased $334,000 (37%) from $914,000 in the 1997 period to $580,000 in the 1998 period primarily as a result of reductions in R&D personnel, payments for research/collaborative projects and travel and meeting costs. Selling, general and administrative expenses increased $204,000 (23%) from $891,000 in the 1997 period to $1,095,000 in the 1998 period primarily as a result of the acquisition of Stellar (for legal and consulting costs relating to the acquisition of Stellar and for Stellar's operations), additional personnel and increased consulting services relating to marketing and promotional efforts for TpP. Interest expense increased by $1,000 (1%) from $126,000 in the 1997 period to $127,000 in the 1998 period, resulting from an increase in the amortized debt issuance cost component of interest expense over the term of the debentures ($64,000 and $41,000 during the second quarters of 1998 and 1997, respectively) offset, in part, by lower principal amount of convertible debentures outstanding during the 1998 period. Upon conversion of the Company's 7% and 8% Convertible Debentures ($950,000 and $4,320,000 during the second quarters of 1998 and 1997, respectively), the related unamortized debt issuance costs ($9,000 and $174,000 during the second quarters of 1998 and 1997, respectively) are charged to paid-in capital. Page 15 Investment income decreased $66,000 (44%) from $151,000 in the 1997 period to $85,000 in the 1998 period as a result of lower average cash balances offset, in part, by slightly higher interest rates on U.S. Government obligations in which most of the Company s available cash is invested. Six Months Ended June 30, 1998 The Company s net loss decreased $1,514,000 (34%) during the six months ended June 30, 1998 from a loss of $4,427,000 during the 1997 period to a loss of $2,913,000 in the 1998 period. The reduction in the net loss is attributable to the gross profit ($229,000 or 68%) on product sales of Stellar and sales of TpP kits, reduced R&D expenses ($896,000), interest expense ($637,000), offset by increased SGA ($154,00) and reduced investment income ($155,000). Sales during the six months ended June 30, 1998 were $441,000, consisting of sales of Stellar products since the date of acquisition of Stellar in late April 1998 and sales of TpP by the Company, sales of which products commenced in the fourth quarter of 1997. Accordingly, there were no sales by the Company in the comparable 1997 period. Cost of sales for the six months ended June 30, 1998 was $142,000 or 32% of sales. Research and development expenses decreased $896,000 (45%) from $1,972,000 in the 1997 period to $1,076,000 in the 1998 period primarily due to the absence of costs incurred during the first six months of 1997 relating to the relocation of the Company's research laboratories from South Bend, Indiana to Boston, Massachusetts. The costs of such relocation included severance, relocation and moving costs as well as duplicate facility costs. Selling, general and administrative expenses increased $154,000 (8%) from $1,977,000 in the 1997 period to $2,131,000 in the 1998 period as a result of increased personnel costs, selling expenses relating to the Page 16 marketing and promotion of TpP and legal and consulting costs relating to the Stellar acquisition. Interest expense decreased $637,000 (78%) from $813,000 in the 1997 period to $176,000 in the 1998 period, resulting from the absence of $492,000 of noncash amortization of the debt discount relating to the Company's 7% Convertible Debentures included in the first quarter of 1997, and lower outstanding Debentures during the six months ended June 30, 1998. Upon the conversion of the Company's 7% and 8% Convertible Debentures ($1,700,000 and $8,300,000 during the six months of 1998 and 1997, respectively), the related unamortized debt issuance costs ($24,000 and $353,000 during the six months of 1998 and 1997, respectively) are charged to paid-in capital. Investment income decreased $155,000 (48%) from $326,000 in the 1997 period to $171,000 in the 1998 period as a result of lower average cash balances offset, in part, by slightly higher interest rates on U.S. Government obligations in which most of the Company s available cash is invested. Liquidity and Capital Resources As of June 30, 1998, the Company had working capital of $7,222,000 compared to $6,961,000 at December 31, 1997. The Company's management believes that current working capital will be sufficient to fund its liquidity needs beyond 1998. During the six months ended June 30, 1998, the Company's cash position increased by $540,000 to $7,661,000. Operating activities used $2,043,000 in cash (resulting primarily from a cash loss of $2,549,000, net of non cash expenses of $364,000, offset, in part, by cash provided by a net change in operating assets and liabilities of $506,000 arising from an increase in accounts payable and accrued expenses of $736,000 offset, in part, primarily from an increase of $198,000 in accounts receivable resulting from product sales and the Company's acquisition of Stellar). Investing activities used $229,000 in cash (primarily related to the acquisition of Stellar and payments for patent costs and fixed assets). Financing activities provided a net of $2,812,000 in cash, Page 17 principally from the sale of $4,000,000 principal amount 5% Convertible Debentures for $3,727,000, after expenses, offset, in part, primarily by payments made in lieu of issuing shares of Class A Common Stock to holders of the Company's 7% Convertible Debentures upon conversion thereof. During the six months ended June 30, 1998, $1,350,000 of the 7% Convertible Debentures and $350,000 of the 8% Convertible Debentures were converted into an aggregate of 851,618 Class A Common Stock. The Company expects to continue to incur substantial expenditures relating to new diagnostic and therapeutic product development, ongoing clinical studies for TpP, marketing and manufacturing of TpP and the Company's FiF reagents and kits, developing point of care (POC) formats for TpP, additional preclinical development of neurological compounds (ABS 103 and ABS 205), additional investment in Stellar's product line by filing 510K's for FDA approval and developing new monoclonal antibodies and products based on the proprietary antigen free mouse technology. In addition, the Company is seeking strategic acquisitions of products and/or companies which may entail the use of cash, issuance of stock or debt. While the Company has begun marketing its products directly, its product development plans still include entering into collaborative, licensing and co-marketing arrangements with other diagnostic and pharmaceutical companies to provide additional funding and clinical expertise to perform tests necessary to obtain regulatory approvals, provide manufacturing expertise and market the Company's products. Without such collaborative, licensing or co-marketing arrangements, additional sources of funding will be required to finance the Company. Year 2000 The Company has been assessing the impact of the Year 2000 issue on its information systems. In connection with these assessments, which are ongoing, the Company has identified potential deficiencies and is addressing them through upgrades and other remediation. In accordance with accounting rules, costs associated with modifying existing computer software for Year 2000 will be expensed as incurred. In addition, the Page 18 Company is in the process of evaluating the measures being undertaken by its critical customers and suppliers to address the Year 2000 issues. The cost of implementing the upgrades and remediations are not expected to be material to the Company's results of operations. PART II OTHER INFORMATION Item 2. Changes in Securities During the three months ended June 30, 1998, holders of $300,000 of the Company's 8% Convertible Debentures and $650,000 of the Company's 7% Convertible Debentures converted such debentures into 360,376 and 219,990 shares of the Company's Class A Common Stock, respectively. The Company believes that the exemption from registration afforded by Section 3(a)(9) of the Securities Act of 1933, as amended (the "Act"), is applicable to the issuances of such shares, as such issuances involved a security exchanged by the Company with existing securityholders exclusively where no commission or other remuneration was paid or given directly or indirectly for soliciting such exchanges. In connection with a lease agreement for certain facilities, the Company may, at its option, pay a portion of the annual lease obligation with Class A Common Stock (the "Issued Shares") plus a warrant (the "Warrant") to purchase shares of Class A Common Stock (the "Warrant Shares"). The number of Issued Shares are computed using the average market price of the Company's Class A Common Stock during the ten days prior to issuance. Each Warrant is exercisable during a period of four years from the date of issuance at a price equal to the closing price of the underlying Class A Common Stock on the date the Warrant is issued. Pursuant to the lease agreement, on May 31, 1998, the Company issued 25,528 shares of Class A Common Stock and a Warrant to purchase 25,528 shares of Class A Common Stock at an exercise price of $1.38 per share. In connection with such acquisition, the purchaser (an accredited investor) agreed to acquire the Issued Shares, the Warrant and the Page 19 Warrant Shares for investment and not with a view to the distribution of such securities. In connection therewith, the Company has granted the purchaser certain rights to cause the Warrant Shares to be registered under the Act at the Company's expense. The Company believes that the exemption from registration afforded by Section 4(2) of the Act is applicable to the issuance of such securities. Reference is made to Note 5 of the Notes to the Consolidated Financial Statements on Part I of this Report for information concerning a private placement completed on May 20, 1998 of an aggregate of $4,000,000 of 5% Convertible Debentures due May 20, 2001 (the "Debentures"), and three series of Warrants to purchase up to an aggregate of 261,288 shares of the Company's Class A Common Stock (the "Warrants"), which information (including information concerning the terms of the conversion of the Debentures and exercise of the Warrants) is incorporated herein by reference. The Debentures and Warrants, which were sold for cash of $4,000,000, were placed through Jesup & Lamont Securities Corp., which acted as placement agent for the transaction, and received a commission of $200,000. Each of the three accredited investor purchasers, acknowledged that it was purchasing the Debentures, the Warrants and the Company's Class A Common Stock issuable upon conversion of the Debentures and the exercise of the Warrants for investment, for its own account and not with a view towards their distribution. The Company believes that the exception afforded by Section 4(2) of the Act is applicable to the issuance of the Debentures and the Warrants. Item 4. Submission of Matters to a Vote of Security Holders At the Company s 1998 Annual Meeting of Stockholders held on June 18, 1998: (a) The following seven directors, each of whom were nominated by the Board of Directors, were elected by the following votes: Voting Authority For Abstain Alfred J. Roach 33,442,515 688,057 Page 20 Stephen H. Ip 33,632,772 497,800 Ellena M. Byrne 33,667,072 463,500 Timothy J. Roach 33,505,770 624,802 Gustav V. R. Born 33,631,672 498,900 Joseph C. Hogan 33,625,672 504,900 William G. Sharwell 33,644,427 486,145 (b) Ratified the appointment of Arthur Andersen LLP to serve as the Company s independent auditors for the year ending December 31, 1998 by the following vote: For Against Abstain 33,852,621 203,955 73,996 (c) Adopted an amendment to the Company's 1996 Stock Option Plan to increase the number of shares of Common Stock which may be issued thereunder from 1,000,000 to 2,000,000 shares. For Against Abstain Broker Non-Votes 22,202,367 1,615,996 249,481 10,062,728 Each matter was approved by the vote of Common Class A and Class B stockholders voting together as one class, with each share of Class A having one vote and each share of Class B having ten votes. Item 5. Other Events At the annual meeting of the Board of Directors, following the annual meeting of the Stockholders on June 18, 1998, the Board elected the following as the executive officers of the Company. Name Position Alfred J. Roach Chairman of the Board and Chief Executive Officer Stephen H. Ip President and Chief Operating Officer Page 21 Emer Leahy Senior Vice President Business Development Ellena M. Byrne Executive Vice President-Global Scientific Network James H. McLinden Vice President-Molecular Biology George Christoffersen Vice President-Research and Development Josef C. Schoell Vice President Finance Timothy J. Roach Treasurer and Secretary Item 6. Exhibits and Reports on Form 8-K (a) Exhibits 27 Financial Data Schedule (b) Reports on Form 8-K The Company filed two reports on Form 8-K during the quarter ended June 30, 1998, dated (date of earliest event reported) April 27, 1998 (as filed on April 28, 1998) and May 20, 1998 (as filed on June 3, 1998), both reporting under Item 5, Other Events. No financial statements were filed with either report. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMERICAN BIOGENETIC SCIENCES,INC. (Registrant) Date: August 13, 1998 /s/ Josef C. Schoell ----------------------- Josef C. Schoell Vice President, Finance (Principal Financial and Accounting Officer) Page 22